Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain

被引:17
作者
Dahmen, N
Fischer, V
Hodl, P
Rujescu, D
Reuss, S
Bartoszyk, GD
Hiemke, C
机构
[1] UNIV MAINZ, DEPT PSYCHIAT, D-55131 MAINZ, GERMANY
[2] UNIV MAINZ, DEPT ANAT, D-55099 MAINZ, GERMANY
[3] E MERCK AG, DEPT CNS RES, D-64271 DARMSTADT, GERMANY
关键词
neuroleptics; sigma binding sites; c-fos; EMD; 57445;
D O I
10.1016/0924-977X(96)00026-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Based on animal studies it has been reasoned that ligands to sigma binding sites might be effective in the treatment of schizophrenic disorders and may also be used to investigate this largely elusive disorder on a molecular level. Expression patterns of c-fos in rat brain were studied following treatment with single doses of the sigma ligand EMD 57445 (0.3, 1, 3, 30 mg/kg s.c.). Specific c-fos gene expression was detected at all concentrations tested in various cortical areas. The signals observed were dose-dependent with the highest intensities in the piriform cortex. Strong signals were also detected in hippocampal areas CA 1,2,3 and the gyrus dentatus, as well as in the medial habenula nuclei. In the caudate putamen, nucleus accumbens and lateral septal nucleus signals were detectable after administration of doses greater than or equal to 1 mg/kg. Furthermore, c-fos hybridization was visible in the amygdala,in the mammillary bodies, the islands of Calleja and in the olfactory tubercle. In the hypothalamus, c-fos expression was seen in the median eminence area after 30 mg/kg EMD 57445. No hybridization signals were obtained in brainstem or cerebellum. Since c-fos expression induced by EMD 57445 resembled the pattern obtained with atypical neuroleptics and studies on animal behavior point to antipsychotic activity, it is concluded that the drug might be suitable in the treatment of schizophrenia.
引用
收藏
页码:237 / 243
页数:7
相关论文
共 45 条
  • [1] Bartoszyk G. D., 1992, Society for Neuroscience Abstracts, V18, P548
  • [2] Bartoszyk GD, 1996, CNS DRUG REV, V2, P175
  • [3] BORISON RL, 1991, PSYCHOPHARMACOL BULL, V27, P103
  • [4] Bowen W. D., 1992, Society for Neuroscience Abstracts, V18, P456
  • [5] METABOLITES OF HALOPERIDOL DISPLAY PREFERENTIAL ACTIVITY AT SIGMA-RECEPTORS COMPARED TO DOPAMINE D-2 RECEPTORS
    BOWEN, WD
    MOSES, EL
    TOLENTINO, PJ
    WALKER, JM
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 177 (03) : 111 - 118
  • [6] GBR-12909 AND FLUSPIRILENE POTENTLY INHIBITED BINDING OF [H-3] (+)3-PPP TO SIGMA-RECEPTORS IN RAT-BRAIN
    CONTRERAS, PC
    BREMER, ME
    RAO, TS
    [J]. LIFE SCIENCES, 1990, 47 (22) : PL133 - PL137
  • [7] AUTORADIOGRAPHIC DISTRIBUTION OF NONDOPAMINERGIC BINDING-SITES LABELED [H-3] HALOPERIDOL IN RAT-BRAIN
    CONTRERAS, PC
    QUIRION, R
    GEHLERT, DR
    CONTRERAS, ML
    ODONOHUE, TL
    [J]. NEUROSCIENCE LETTERS, 1987, 75 (02) : 133 - 140
  • [8] DEBONNEL G, 1993, J PSYCHIATR NEUROSCI, V18, P157
  • [9] A NEW APPROACH TO THE DESIGN OF SIGMA-2-SELECTIVE LIGANDS - SYNTHESIS AND EVALUATION OF N-[2-(3,4-DICHLOROPHENYL)ETHYL]-N-METHYL-2(1-PYRROLIDINYL)ETHYLAMINE-RELATED POLYAMINES AT SIGMA-1 AND SIGMA-2 RECEPTOR SUBTYPES
    DECOSTA, BR
    HE, XS
    DOMINGUEZ, C
    CUTTS, J
    WILLIAMS, W
    BOWEN, WD
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (02) : 314 - 321
  • [10] THE SIGMA-RECEPTOR - A NOVEL SITE IMPLICATED IN PSYCHOSIS AND ANTIPSYCHOTIC DRUG EFFICACY
    DEUTSCH, SI
    WEIZMAN, A
    GOLDMAN, ME
    MORIHISA, JM
    [J]. CLINICAL NEUROPHARMACOLOGY, 1988, 11 (02) : 105 - 119